SCHEMBL7703038

SCHEMBL7703038

CC(=O)Nc1ccc(Oc2ccc(C(=O)N[C@@H]3C4CCN(CC4)[C@H]3C)cc2)[nH]1.NC(=O)c1ccc(Oc2ccc(N3CCOCC3)[nH]2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 2/20 0.33
JAK3 P52333 2/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
BTK Q06187 2/20 0.33
HPGD P15428 1/20 0.32
MAPT P10636 2/20 0.32
ATM Q13315 1/20 0.32
MTOR P42345 2/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
SIRT2 Q8IXJ6 1/20 0.32
SIRT1 Q96EB6 1/20 0.32
SIRT3 Q9NTG7 1/20 0.32
LMNA P02545 1/20 0.32
HIF1A Q16665 1/20 0.31
EPAS1 Q99814 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6872605 0.89 CNR1 (0.38) CHRNB2CHRNA7CHRNA4MEN1KMT2A
SCHEMBL6872744 0.87 CHRNB2 (0.41) CHRNB2CHRNA7CHRNA4MEN1KMT2A
SCHEMBL6872752 0.77 CHRNB2 (0.40) LCKJAK3CHRNB2CHRNA7CHRNA4
SCHEMBL6882272 0.77 PARP10 (0.45) CHRNB2CHRNA7CHRNA4KMT2AHPGD
SCHEMBL6882039 0.75 CHRNA7 (0.41) CHRNB2CHRNA7CHRNA4GAAALDH1A1
SCHEMBL6880032 0.75 CHRNB2 (0.38) CHRNB2CHRNA7CHRNA4MEN1KMT2A
SCHEMBL6882422 0.74 CHRNB2 (0.40) CHRNB2CHRNA7CHRNA4MEN1KMT2A
SCHEMBL6884750 0.74 CHRNB2 (0.41) CHRNB2CHRNA7CHRNA4MEN1KMT2A
SCHEMBL6883422 0.74 CHRNB2 (0.46) CHRNB2CHRNA7CHRNA4MEN1KMT2A
SCHEMBL6875123 0.74 CHRNB2 (0.41) CHRNB2CHRNA7CHRNA4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486172-B2 ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS PHARMACIA & UPJOHN COMPANY 2002-11-26 US disclosed